PBAC
Keeping up to date
PBAC reveals the latest raft of new recommendations made on PBS drugs The latest recommendations made by the Pharmaceutical Benefits Advisory Committee have been released, with new listings for naloxone …
Blockbuster alert
Nine new blockbuster drugs headed our way soon: report A series of new ‘blockbuster’ drugs are expected to hit Australian shores in the next 12-24 months, a new report claims. …
PrEP listing decision deferred
An HIV prevention advocate has vowed to keep fighting for pre exposure prophylaxis to be PBS listed Following the announcement by the Pharmaceutical Benefits Advisory Committee that it will defer …
CHF get a new seat on PBAC
Consumers’ group deputy head now gains a senior role on key PBS committee Federal Health Minister Greg Hunt has announced that Jo Watson, deputy chair of the Consumers Health Forum …
Warning on biosimilar burden
A higher than usual degree of pharmacovigilance is required when patients are switched to new biosimilar medications, say Australian experts Writing in the latest Australian Prescriber two pharmacy academics have stressed …
Use of warfarin is in decline
But NOACs have contributed to an overall growth in the anticoagulant market Based on the volume of prescriptions, use of novel oral anticoagulants (NOACs) in Australia has grown since their …
Panadol Osteo decision could shift patients to opioids
Stakeholders have expressed disappointment in the PBAC’s restatement of its decision to delist Panadol Osteo, and concerns that patients may turn to stronger alternatives to manage their pain. The PBAC …
Panadol Osteo, admit it was a mistake: Guild
It is time the government ‘fessed up’ that Panadol Osteo has been de-listed from the PBS by mistake, says the Guild today. It says that in April last year PBAC set very clear criteria …
Panadol Osteo referral: a first for the Minister
It is the first time Health Minister Sussan Ley has referred a company to the ACCC due to the “unique” circumstances surrounding the price rise for Panadol Osteo, a spokesman for …
PBS listings need review: Guild
An urgent review is needed of the de-listing of some medicines which were available on the PBS and now will cost more OTC, says the Guild.The Guild has written to the Pharmaceutical Benefits …
PWC outlines medicines industry challenges: Medicines Australia
The 2015 PricewaterhouseCoopers survey of the Australian medicines industry provides an important and timely insight into the challenges and opportunities confronting the Australian innovative medicines industry, says Medicines Australia. The …
Regulatory headaches stifling access to medicines: PwC report
TGA regulation, price pressure and compliance issues are reducing access to medicines, and reducing industry confidence, a PwC report claims. Challenges and Change—a report on the Australian pharmaceutical industry, released …